Sign in

    Mathieu Chevrier

    Research Analyst at Citigroup Inc.

    Mathieu Chevrier is the Head Vice President of Healthcare Research for Australia and New Zealand at Citigroup, specializing in equity analysis of leading healthcare companies such as ResMed, CSL, EBO, and NAN. He covers 18 stocks with a reported success rate of 40.3% and has achieved notable performance including a +34.6% return from a sell rating on NAN between August 2023 and August 2024. Chevrier began his analyst career prior to joining Citigroup, where he currently leads healthcare sector research, and brings years of experience in stock ratings and sector analysis. He holds professional credentials relevant to research and trading within investment banking and securities analysis.

    Mathieu Chevrier's questions to RESMED (RMD) leadership

    Mathieu Chevrier's questions to RESMED (RMD) leadership • Q2 2025

    Question

    Mathieu Chevrier from Citi asked if ResMed sees a need for more research and education on the benefits of CPAP, given the aggressive expansion of indications for GLP-1 drugs by pharmaceutical companies.

    Answer

    Executive Michael Farrell strongly agreed, stating he has challenged his medical team to increase the velocity and quality of research using ResMed's vast real-world data. He cited existing peer-reviewed studies on mortality reduction and cost savings, and emphasized the need to publish more outcome-focused data. He believes this research is crucial to reinforce CPAP's value, especially as awareness driven by pharma and consumer tech grows.

    Ask Fintool Equity Research AI